122 related articles for article (PubMed ID: 37742997)
1. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
3. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
[TBL] [Abstract][Full Text] [Related]
4. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Takubo H; Bessho K; Watari R; Shigemi R
Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
[TBL] [Abstract][Full Text] [Related]
5. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
6. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
8. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
9. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
10. Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.
Suzuki Y; Sasamoto Y; Koyama T; Yoshijima C; Nakatochi M; Kubo M; Momozawa Y; Uehara R; Ohno K
Clin Transl Sci; 2021 Jan; 14(1):382-388. PubMed ID: 32961019
[TBL] [Abstract][Full Text] [Related]
11. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
Lai Y
Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
[TBL] [Abstract][Full Text] [Related]
12. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
13. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
[TBL] [Abstract][Full Text] [Related]
15. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
[TBL] [Abstract][Full Text] [Related]
16. Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin-I and blood concentration of cyclosporin A in real-world patients.
Watanabe T; Tanaka R; Suzuki Y; Sato H; Negami J; Yoshijima C; Oda A; Ono H; Tatsuta R; Ohno K; Itoh H
Br J Clin Pharmacol; 2023 May; 89(5):1672-1681. PubMed ID: 36517987
[TBL] [Abstract][Full Text] [Related]
17. Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
Kikuchi R; Chothe PP; Chu X; Huth F; Ishida K; Ishiguro N; Jiang R; Shen H; Stahl SH; Varma MVS; Willemin ME; Morse BL
Clin Pharmacol Ther; 2023 Dec; 114(6):1170-1183. PubMed ID: 37750401
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
19. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
